Drugs / Zotiraciclib
Trials 8
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-26 | Cothera Bioscience, Inc | Regulatory FDA Grants Fast Track Designation to Cothera Bioscience’s Zotiraciclib for Treatment of Recurrent High-Grade Glioma with IDH1/2 Mutations cotherabio.com ↗
Cothera Bioscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zotiraciclib (ZTR/TG02) for the treatment of patients with recurrent high-grade gliomas (rHGG) harboring IDH1 or IDH2 mutations (IDHmut rHGG). |
| 2017-12-18 | Targovax Oy | Results Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer circio.com ↗
No issues were reported, and it has been recommended that the trial should continue. |
| 2016-06-02 | Targovax Oy | Regulatory Targovax receives approval in Australia to conduct a clinical trial with TG02 – an immunotheraphy treatment targeting RAS mutations circio.com ↗
Targovax receives approval to conduct a study with TG02 and pembrolizumab, a checkpoint inhibitor, in patients with locally recurrent RAS mutated rectal cancer. |
All press releases naming this drug 7 releases
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zotiraciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05588141 ↗ |
| Known as | EX45 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗ |
| Known as | SB-1317 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗ |
| Known as | Sb-1317 free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗ |
| Known as | TG02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02933944 ↗ |
| Known as | TG02 Citrate | “Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma” NCT03738111 ↗ |
| Known as | ZOTIRACICLIB CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1944698 ↗ |
| Known as | ZTR | “Here, by conducting a high-throughput drug screen, we pinpointed a specific vulnerability of IDH-mutant gliomas to zotiraciclib (ZTR).” PMID 40241769 ↗ Mar 2025 |
| Action | Inhibit | “Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on cyclin-dependent kinases (CDKs), Janus Kinase 2 (JAK2) and...” NCT02942264 ↗5“Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1944698 ↗ “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL1944698 ↗ “Cyclin-dependent kinase 2 inhibitor” CHEMBL1944698 ↗ “Cyclin-dependent kinase 1 inhibitor” CHEMBL1944698 ↗ “Cyclin-dependent kinase 7 inhibitor” CHEMBL1944698 ↗ |
| Modality | Small molecule | — CHEMBL1944698 ↗ |
| Route | Oral | “TG02 citrate capsules given orally.” NCT01204164 ↗ |
| Target | CDK1 | “Cyclin-dependent kinase 1 inhibitor” CHEMBL1944698 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL1944698 ↗ |
| Target | CDK7 | “Cyclin-dependent kinase 7 inhibitor” CHEMBL1944698 ↗ |
| Target | CDK9 | “Zotiraciclib (TG02) down-regulates cyclin-dependent kinase 9 (CDK9) activity” NCT02942264 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1944698 ↗ |
| Target | JAK2 | “Tyrosine-protein kinase JAK2 inhibitor” CHEMBL1944698 ↗ |